-
Mashup Score: 3UK MHRA Approves GSK’s BLENREP® in Combination with BVd and BPd for the Treatment of Adult RRMM Patients - 16 day(s) ago
UK Medicine and Healthcare products Regulatory Agency (MHRA) authorizes use of Blenrep (belantamab mafodotin) for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in patients who have received at least one prior therapy including lenalidomide.
Source: www.myeloma.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1About Myelo - 1 month(s) ago
Ever have a question about myeloma pop up at 3 am, leaving you frustrated and searching for answers? Now you can get the answers you need, anytime. Say hello to Myelo, your 24/7 Generative AI assistant specifically designed to support you on your myeloma journey.
Source: www.myeloma.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @NorthTxMSG: 2/ That belief led to Myelo™ (https://t.co/IIP8viuzOK), an AI-powered personal assistant developed to provide readily acces…
-
-
Mashup Score: 278International Myeloma Foundation - 2 month(s) ago
{node:summary]
Source: www.myeloma.orgCategories: General Medicine News, PayerTweet-
🧠Knowledge is power in the fight against #MultipleMyeloma. @IMFmyeloma’s personalized education resources provide relevant & timely information to help patients navigate their myeloma journey. 🔗 Learn more: https://t.co/Tj7GNSN9pw #MyelomaActionMonth https://t.co/7dugye69Ju
-
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrqt4p #mmMRD #mmsm #ctsm @FDAOncology https://t.co/cABSxMTt0d
-
-
Mashup Score: 1International Myeloma Foundation - 8 month(s) ago
{node:summary]
Source: www.myeloma.orgCategories: General Medicine News, PayerTweet-
#MultipleMyeloma is a challenging blood cancer marked by cycles of remission and relapse. @IMFMyeloma provides resources to support patients & caregivers throughout their treatment journey. 🔗 Learn more: https://t.co/nkrDMMnWHR #BloodCancerAwarenessMonth https://t.co/fMRBBLnH5C
-
-
Mashup Score: 2
IMF Chief Scientific Officer Dr. Brian G.M. Durie discusses the details and outcome of the recent April 12th Oncologic Drugs Advisory Committee meeting on “the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding timing of assessment, patient populations, and trial design for future studies that intend to use MRD to support accelerated approval of a new product or a new indication.”
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrqt4p #mmMRD #mmsm #ctsm @FDAOncology https://t.co/cABSxMTt0d
-
-
Mashup Score: 30M-Power New York: Community Workshop 2024 - 11 month(s) ago
Don’t miss this New York community event to discuss health empowerment. We will focus on awareness of multiple myeloma in the African American community. The panel will share patient stories and suggestions to “M-Power” yourself if ever faced with a complicated diagnosis. Refreshments will be provided.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
Food, Blood, and Cancer - Are They Connected? The @IMFmyeloma @MSKCancerCenter and the Abyssinian Baptist Church, have organized an in-person M-Power Public Information Dinner on June 20, 2024, in NYC @NorthTxMSG @jmikhaelmd https://t.co/VPSV8jGAzK #mmsm #cancer #prevention https://t.co/FBCJXbdi2y
-
-
Mashup Score: 1Top Myeloma Research Presented at ASCO & EHA Webinar 2024 - 11 month(s) ago
Discover the top multiple myeloma research presented at ASCO and EHA 2024 in this informative webinar.
Source: www.myeloma.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @blondie1746: I hope you can join us for this important presentation! #mmsm #myeloma #multiplemyeloma https://t.co/zWE7UoKt9Y https://t.…
-
-
Mashup Score: 8IMWG Scientific and Working Committees - 11 month(s) ago
The International Myeloma Working Group has a scientific committee and a few working committees. Here are their members.
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
IMWG Steering Committee and Scientific Committees. https://t.co/tQ6sxZ3COI
-
-
Mashup Score: 21International Myeloma Working Group (IMWG) Publications - 11 month(s) ago
The International Myeloma Working Group (IMWG) has published dozens of research studies and treatment guidelines on multiple myeloma and its related disorders. The following are a sample of the International Myeloma Working Group’s ranging publication topics:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet-
@paurotero @JKaufmanMD @szusmani @YiLinMDPhD @TomBmt133 @DrRakeshPopat @AjayNookaMD @H_Einsele @SurbhiSidanaMD @AjaiChari @End_myeloma @KweeYong2 @NoopurRajeMD @jmikhaelmd @chngwj @MyelomaOslo @JaimeLarraya @IMFmyeloma Here is a link to all prior IMWG guidelines and consensus statements. https://t.co/OsCjtEigdJ
-
RT @JoshuaRichterMD: UK MHRA Approves Blenrep Combinations for RRMM| Int'l Myeloma Fn. #mmsm @IMFmyeloma https://t.co/lruxVQNDLX